Literature DB >> 22910846

Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients.

Dario Ribero, Antonio Daniele Pinna, Alfredo Guglielmi, Antonio Ponti, Gennaro Nuzzo, Stefano Maria Giulini, Luca Aldrighetti, Fulvio Calise, Giorgio Enrico Gerunda, Mariano Tomatis, Marco Amisano, Pasquale Berloco, Guido Torzilli, Lorenzo Capussotti.   

Abstract

OBJECTIVES To examine the outcomes of a hepatectomy for intrahepatic cholangiocarcinoma (IHC) and to clarify the prognostic impact of a lymphadenectomy and the surgical margin. Large series of patients who were surgically treated for IHC are scarce. Thus, prognostic factors and long-term survival after resection of IHC remain uncertain. DESIGN Prospective study of patients who were surgically treated for IHC. Clinicopathologic, operative, and long-term survival data were analyzed. SETTING Prospectively collected data of all consecutive patients with pathologically confirmed IHC who had undergone liver resection with a curative intent at 1 of 16 tertiary referral centers were entered into a multi-institutional registry. PATIENTS All consecutive patients who underwent a hepatectomy with a curative intent for IHC (1990-2008) were identified from a multi-institutional registry. RESULTS A total of 434 patients were included in the analysis. Most patients underwent a major or extended hepatectomy (70.0%) and a systematic lymphadenectomy (62.2%). The incidence of lymph node metastases (overall, 36.9%) increased with increased tumor size, with 24.4% of patients with a small IHC (diameter ≤3 cm) having N1 disease. Almost one-third of patients required an additional major procedure to obtain a R0 resection in 84.6% of the cases. In these patients, the median time of survival was 39 months, and the 5-year survival rate was 39.8%. Lymph node metastases (hazard ratio, 2.21; P < .001), multiple tumors (hazard ratio, 1.50; P = .009), and an elevated preoperative cancer antigen 19.9 level (hazard ratio, 1.62; P = .006) independently predicted an adverse prognosis. Conversely, survival was not influenced by the width of a negative resection margin (P = .61). The potential survival benefit of a lymphadenectomy was assessed with the therapeutic value index, which was calculated to be 5.9 points. CONCLUSIONS Survival rates after a hepatectomy with a curative intent for IHC at tertiary referral centers exceed the survival rates reported in most study series in single institutions, which strengthens the value of an aggressive approach to radical resection. Lymph node metastases and multiple tumors are associated with decreased survival rates, but they should not be considered selection criteria that prevent other patients from undergoing a potentially curative resection. Lymphadenectomy should be considered for all patients.

Entities:  

Year:  2012        PMID: 22910846     DOI: 10.1001/archsurg.2012.1962

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  94 in total

Review 1.  Staging of intrahepatic cholangiocarcinoma.

Authors:  Sean M Ronnekleiv-Kelly; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

2.  Segment 5 parenchymal sparing in extended left hepatectomy with respect to venous outflow-is it a feasible procedure?

Authors:  Jun Li; Moustafa Mohamed; Lutz Fischer; Björn Nashan
Journal:  Langenbecks Arch Surg       Date:  2018-06-28       Impact factor: 3.445

3.  Factors affecting survival after resection of intrahepatic cholangiocarcinoma.

Authors:  Sae Murakami; Tetsuo Ajiki; Taro Okazaki; Kimihiko Ueno; Masahiro Kido; Ippei Matsumoto; Takumi Fukumoto; Yonson Ku
Journal:  Surg Today       Date:  2014-01-23       Impact factor: 2.549

4.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

Review 5.  Surgical treatment for intrahepatic cholangiocarcinoma.

Authors:  Takahiro Uenishi; Takatsugu Yamamoto; Shigekazu Takemura; Shoji Kubo
Journal:  Clin J Gastroenterol       Date:  2014-02-15

Review 6.  The value of systematic lymph node dissection for intrahepatic cholangiocarcinoma from the viewpoint of liver lymphatics.

Authors:  Yuji Morine; Mitsuo Shimada
Journal:  J Gastroenterol       Date:  2015-04-02       Impact factor: 7.527

7.  Oncologic Impact of Lymph Node Dissection for Intrahepatic Cholangiocarcinoma: a Propensity Score-Matched Study.

Authors:  Sung Hyun Kim; Dai Hoon Han; Gi Hong Choi; Jin Sub Choi; Kyung Sik Kim
Journal:  J Gastrointest Surg       Date:  2018-08-15       Impact factor: 3.452

Review 8.  Epidemiology and surgical management of intrahepatic cholangiocarcinoma.

Authors:  Han Zhang; Feng Shen; Jun Han; Yi-Nan Shen; Guo-Qiang Xie; Meng-Chao Wu; Tian Yang
Journal:  Hepat Oncol       Date:  2015-11-30

9.  Patterns and prognostic significance of lymph node dissection for surgical treatment of perihilar and intrahepatic cholangiocarcinoma.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Tommaso Campagnaro; Alessandro Valdegamberi; Fabio Bagante; Francesca Bertuzzo; Simone Conci; Calogero Iacono
Journal:  J Gastrointest Surg       Date:  2013-09-19       Impact factor: 3.452

Review 10.  Hepatitis B virus and hepatitis C virus play different prognostic roles in intrahepatic cholangiocarcinoma: A meta-analysis.

Authors:  Zheng Wang; Yuan-Yuan Sheng; Qiong-Zhu Dong; Lun-Xiu Qin
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.